Telix Posts 22% Revenue Growth, Boosted by Regeneron Deal and Pipeline Momentum
Event summary
- Telix reported H1 2026 revenue of US$477 million, up 22% YoY, tracking toward US$1 billion in FY 2026.
- Adjusted EBITDA surged 146% YoY to US$52 million, driven by strong demand and a US$40 million Regeneron collaboration payment.
- Precision Medicine segment revenue grew 27% YoY, with Illuccix® and Gozellix® gaining market share.
- Telix invested US$124 million in R&D, advancing late-stage therapeutics for prostate, brain, and kidney cancers.
- The company established an 'at-the-market' equity facility with Morgan Stanley and William Blair for future share issuances.
The big picture
Telix's strong H1 2026 results reflect the growing adoption of its prostate cancer imaging portfolio and strategic bets on next-generation radiopharmaceuticals. The Regeneron collaboration and expanded manufacturing footprint position the company to compete in the rapidly evolving theranostics market, where precision diagnostics and targeted therapies are gaining traction. With multiple late-stage assets in pivotal trials, Telix is poised to diversify its revenue streams beyond diagnostics.
What we're watching
- Regulatory Catalysts
- The FDA's September 2026 PDUFA goal date for Pixclara® and progress on Zircaix® resubmission will shape near-term commercialization prospects.
- Pipeline Execution
- The pace of enrollment and data readouts in ProstACT Global (prostate cancer) and LUTEON (kidney cancer) trials will determine therapeutic revenue timelines.
- Capital Allocation
- How Telix balances R&D investment with manufacturing expansion and potential share issuances under its new ATM facility.
Related topics